{"id":"ketamine-2st-phase","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased blood pressure"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ketamine antagonizes N-methyl-D-aspartate (NMDA) receptors, which are ionotropic glutamate receptors involved in excitatory neurotransmission. By blocking these receptors in a use-dependent manner, ketamine disrupts pain signal transmission and produces dissociative anesthesia. At sub-anesthetic doses, ketamine has shown rapid antidepressant effects, potentially through increased synaptic plasticity and AMPA receptor potentiation.","oneSentence":"Ketamine is a non-competitive NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset dissociative anesthesia and analgesic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:57.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression (marketed/clinical use)"},{"name":"Acute suicidal ideation and behavior"},{"name":"Anesthesia induction and maintenance"},{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT02644629","phase":"PHASE4","title":"Intra-nasal vs. Intra-venous Ketamine Administration","status":"COMPLETED","sponsor":"Shalvata Mental Health Center","startDate":"2016-04","conditions":"Major Depressive Disorder","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ketalar"],"phase":"marketed","status":"active","brandName":"Ketamine (2st phase)","genericName":"Ketamine (2st phase)","companyName":"Shalvata Mental Health Center","companyId":"shalvata-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketamine is a non-competitive NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset dissociative anesthesia and analgesic effects. Used for Treatment-resistant depression (marketed/clinical use), Acute suicidal ideation and behavior, Anesthesia induction and maintenance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}